Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Mar;38(3):563–569. doi: 10.1128/aac.38.3.563

Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-alpha-difluoromethylornithine and standard trypanocides.

C J Bacchi 1, H C Nathan 1, N Yarlett 1, B Goldberg 1, P P McCann 1, A Sjoerdsma 1, M Saric 1, A B Clarkson Jr 1
PMCID: PMC284498  PMID: 8203855

Abstract

Combinations of DL-alpha-difluoromethylornithine (DFMO; eflornithine; Ornidyl) with either suramin or melarsen oxide were found to be effective against acute laboratory model infections with Trypanosoma brucei rhodesiense. We used clinical isolates known to be resistant to these drugs when used singly. An infection with a melarsen oxide-refractory isolate was cured by a combination of low-dose DFMO (0.5% in the drinking water) plus low-dose suramin (1 mg/kg of body weight given intraperitoneally). Another strain, moderately resistant to arsenical drugs, was cured with combinations of 4% DFMO with 5 mg of melarsen oxide per kg. Furthermore, a combination of DFMO (2% in the drinking water) and suramin (20 mg/kg) provided a 100% cure rate in a central nervous system model, although the same doses of these drugs used singly were completely ineffective. The synergism of DFMO and suramin against an acute infection was improved when suramin was given at the end of the DFMO administration. No adverse interactions were observed when high doses of DFMO combined with high doses of suramin were administered to uninfected mice. These results suggest that combinations of DFMO and suramin should be examined clinically for activity in arsenical-drug-refractory cases of East African sleeping sickness.

Full text

PDF
563

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apted F. I. Present status of chemotherapy and chemopropylaxis of human trypanosomiasis in the Eastern Hemisphere. Pharmacol Ther. 1980;11(2):391–413. doi: 10.1016/0163-7258(80)90035-2. [DOI] [PubMed] [Google Scholar]
  2. Bacchi C. J., Berens R. L., Nathan H. C., Klein R. S., Elegbe I. A., Rao K. V., McCann P. P., Marr J. J. Synergism between 9-deazainosine and DL-alpha-difluoromethylornithine in treatment of experimental African trypanosomiasis. Antimicrob Agents Chemother. 1987 Sep;31(9):1406–1413. doi: 10.1128/aac.31.9.1406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bacchi C. J., Nathan H. C., Clarkson A. B., Jr, Bienen E. J., Bitonti A. J., McCann P. P., Sjoerdsma A. Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. Am J Trop Med Hyg. 1987 Jan;36(1):46–52. doi: 10.4269/ajtmh.1987.36.46. [DOI] [PubMed] [Google Scholar]
  4. Bacchi C. J., Nathan H. C., Livingston T., Valladares G., Saric M., Sayer P. D., Njogu A. R., Clarkson A. B., Jr Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother. 1990 Jun;34(6):1183–1188. doi: 10.1128/aac.34.6.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bacchi C. J., Nathan H. C., Yarlett N., Goldberg B., McCann P. P., Bitonti A. J., Sjoerdsma A. Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor. Antimicrob Agents Chemother. 1992 Dec;36(12):2736–2740. doi: 10.1128/aac.36.12.2736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bales J. D., Jr, Harrison S. M., Mbwabi D. L., Schecter P. J. Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann Trop Med Parasitol. 1989 Aug;83 (Suppl 1):111–114. doi: 10.1080/00034983.1989.11812414. [DOI] [PubMed] [Google Scholar]
  7. Bitonti A. J., Byers T. L., Bush T. L., Casara P. J., Bacchi C. J., Clarkson A. B., Jr, McCann P. P., Sjoerdsma A. Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrob Agents Chemother. 1990 Aug;34(8):1485–1490. doi: 10.1128/aac.34.8.1485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Carter N. S., Fairlamb A. H. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature. 1993 Jan 14;361(6408):173–176. doi: 10.1038/361173a0. [DOI] [PubMed] [Google Scholar]
  9. Clarkson A. B., Jr, Bacchi C. J., Mellow G. H., Nathan H. C., McCann P. P., Sjoerdsma A. Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis. Proc Natl Acad Sci U S A. 1983 Sep;80(18):5729–5733. doi: 10.1073/pnas.80.18.5729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Clarkson A. B., Jr, Bienen E. J., Bacchi C. J., McCann P. P., Nathan H. C., Hutner S. H., Sjoerdsma A. New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin. Am J Trop Med Hyg. 1984 Nov;33(6):1073–1077. doi: 10.4269/ajtmh.1984.33.1073. [DOI] [PubMed] [Google Scholar]
  11. Fairlamb A. H., Carter N. S., Cunningham M., Smith K. Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol. 1992 Jul;53(1-2):213–222. doi: 10.1016/0166-6851(92)90023-d. [DOI] [PubMed] [Google Scholar]
  12. Fairlamb A. H., Henderson G. B., Bacchi C. J., Cerami A. In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Mol Biochem Parasitol. 1987 Jun;24(2):185–191. doi: 10.1016/0166-6851(87)90105-8. [DOI] [PubMed] [Google Scholar]
  13. Fairlamb A. H., Henderson G. B., Cerami A. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2607–2611. doi: 10.1073/pnas.86.8.2607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hawking F. Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 1978;15:289–322. doi: 10.1016/s1054-3589(08)60486-x. [DOI] [PubMed] [Google Scholar]
  15. Jennings F. W. Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol. 1992 Jun;43(2):106–109. [PubMed] [Google Scholar]
  16. Jennings F. W. Future prospects for the chemotherapy of human trypanosomiasis. 2. Combination chemotherapy and African trypanosomiasis. Trans R Soc Trop Med Hyg. 1990 Sep-Oct;84(5):618–621. doi: 10.1016/0035-9203(90)90125-x. [DOI] [PubMed] [Google Scholar]
  17. Jennings F. W., Gray G. D. Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes. Contrib Microbiol Immunol. 1983;7:147–154. [PubMed] [Google Scholar]
  18. Jennings F. W. The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis. Bull Soc Pathol Exot Filiales. 1988;81(3 Pt 2):595–607. [PubMed] [Google Scholar]
  19. Jennings F. W., Whitelaw D. D., Urquhart G. M. The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy. Parasitology. 1977 Oct;75(2):143–153. doi: 10.1017/s0031182000062284. [DOI] [PubMed] [Google Scholar]
  20. Van Nieuwenhove S. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop. 1992;72 (Suppl 1):39–51. [PubMed] [Google Scholar]
  21. Yarlett N., Goldberg B., Nathan H. C., Garofalo J., Bacchi C. J. Differential sensitivity of Trypanosoma brucei rhodesiense isolates to in vitro lysis by arsenicals. Exp Parasitol. 1991 Feb;72(2):205–215. doi: 10.1016/0014-4894(91)90138-m. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES